STING1 and melanoma: co-encapsulated the STING agonist cyclic diguanylate monophosphate(cdGMP) and TLR4 pathway agonist monophosphoryl lipid A(MPLA) within lipid nanoparticles, which synergized with PD-1 inhibitors to enhance tumor-clearing CD8+ T cell functionality in melanoma-bearing mice (78).